文献速递肿瘤 PET/CT神经核医学

中期18F-DOPA与18F-FDG PET/CT显像对3-4期儿童神经母细胞瘤的预后价值

Prognostic Value of Interim 18F-DOPA and 18F-FDG PET/CT Findings in Stage 3-4 Pediatric Neuroblastoma.
PubMed 文献 · Clin Nucl Med · 2022-01-01

该回顾性研究纳入32例3-4期儿童神经母细胞瘤患者,在3个化疗周期前后行18F-DOPA和18F-FDG PET/CT,评估代谢与体积参数及代谢负荷评分与临床结局的关联。中位随访47个月,16例进展、13例死亡;校正临床因素后,中期肿瘤FDG/FDOPA SUVmax比及中期FDOPA全身代谢负荷评分是总生存的显著预后因素,仅后者预测无进展生存。

要点

  • 中期肿瘤FDG/FDOPA SUVmax比≥0.57与总生存不良显著相关(P<0.05)。
  • 中期FDOPA全身代谢负荷评分≥21.92与总生存及无进展生存均显著相关(均P<0.05)。
  • 中期FDG与FDOPA PET/CT或可作为3-4期神经母细胞瘤的预后标志物。

核心结论

  • 中期治疗FDG和FDOPA PET/CT或可作为3-4期神经母细胞瘤患者的预后标志物。

研究设计与样本

  • 回顾性研究纳入32例3-4期儿童神经母细胞瘤患者,在3个化疗周期前后行18F-DOPA和18F-FDG PET/CT扫描。

主要发现

  • 中位随访47个月(范围3-137个月)期间,16例患者出现疾病进展,13例死亡。
  • 校正临床因素后,多因素Cox比例风险模型显示中期肿瘤FDG/FDOPA SUVmax比(HR 5.94,95%CI 1.10-34.98)和中期FDOPA全身代谢负荷评分(HR 7.30,95%CI 1.50-35.50)为总生存的显著预后因素。
  • 仅中期FDOPA全身代谢负荷评分(HR 7.05,95%CI 1.02-48.7)可预测无进展生存。
  • 按中位截断值,中期FDOPA全身代谢负荷评分≥21.92与总生存及无进展生存显著相关(均P<0.05),中期肿瘤FDG/FDOPA SUVmax比评分≥0.57与总生存不良显著相关(P<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This retrospective study aimed to determine the prognostic value of imaging parameters derived from midtherapy 18F-fluorodihydroxyphenylalanine (18F-DOPA) and 18F-FDG PET in pediatric patients with stage 3-4 neuroblastoma. METHODS: We enrolled 32 stage 3-4 pediatric neuroblastoma patients who underwent 18F-DOPA and 18F-FDG PET/CT scans before and after 3 chemotherapy cycles. We measured metabolic and volumetric parameters and applied a metabolic burden scoring system to evaluate the primary tumor extent and soft tissue metastases and that of bone/bone marrow involvement. The associations between these parameters and clinical outcomes were investigated. RESULTS: Over a median follow-up period of 47 months (range, 3-137 months), 16 patients experienced disease progression, and 13 died. After adjustment for clinical factors, multivariate Cox proportional hazard models showed that interim tumor FDG/FDOPA SUVmax (hazard ratio [HR], 5.94; 95% confidence interval [CI], 1.10-34.98) and interim FDOPA whole-body metabolic burden scores (WBMB) (HR, 7.30; 95% CI, 1.50-35.50) were significant prognostic factors for overall survival (OS). Only interim FDOPA WBMB scores (HR, 7.05; 95% CI, 1.02-48.7) were predictive of progression-free survival. Based on median cutoff values, prognosis (OS and progression-free survival) was significantly associated with an interim FDOPA WBMB score ≥21.92 (all P < 0.05) and interim tumor FDG/FDOPA (SUVmax) score ≥0.57 with poor OS (P < 0.05). CONCLUSIONS: Our results indicate that midtreatment FDG and FDOPA PET/CT could serve as prognostic markers in stage 3-4 neuroblastoma patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ko KY, Yen RF, Ko CL, et al. Prognostic Value of Interim 18F-DOPA and 18F-FDG PET/CT Findings in Stage 3-4 Pediatric Neuroblastoma. Clin Nucl Med. 2022. PMID: 34874346. doi:10.1097/RLU.0000000000003972

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。